NCT07684599 Mocertatug Rezetecan MSS/pMMR/MSI-L Endometrial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07684599 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07684599 is a hot trial to watch
MSS/pMMR/MSI-L Endometrial Carcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07684599 is notable because it evaluates Mocertatug Rezetecan in a Phase 3 design sponsored by GSK Plc. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07684599 |
| Official title | A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Mocertatug Rezetecan |
| Sponsor | GSK Plc |
| Geography | Not reported in the indexed record |
| Enrollment | 610 |
| Primary endpoint | Progression free survival (PFS) by BICR assessment |
| Endpoint time frame | Up to approximately 151 weeks |
| Primary completion / readout proxy | 2029-07-23 |
Protocol design and endpoint interpretation
The purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug combination is safe and tolerated well by participants compared to the usual care and will help us better understand its impact on Health-Related Quality of Life of participants.
Allocation is Randomized, masking is Single, and the intervention model is Parallel Assignment. Planned enrollment of 610 participants across Not reported in the indexed record shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Progression free survival (PFS) by BICR assessment (Up to approximately 151 weeks) — PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first
Readout outlook and evidence gap
The current protocol points to 2029-07-23 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Mocertatug Rezetecan. The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: GSK Plc. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07684599 provides a focused lens on MSS/pMMR/MSI-L Endometrial Carcinoma development. Its value will be determined by whether Mocertatug Rezetecan can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
